Literature DB >> 15466262

Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.

Masahide Mizobuchi1, Ikuji Hatamura, Hiroaki Ogata, Fumie Saji, Susumu Uda, Kazuhiro Shiizaki, Toshifumi Sakaguchi, Shigeo Negi, Eriko Kinugasa, Shozo Koshikawa, Tadao Akizawa.   

Abstract

The reduced expression level of the calcium-sensing receptor (CaR) is attributed to the hyposensitivity of parathyroid cells to extracellular calcium concentration [Ca2+]o, which plays a crucial role in the pathogenesis of secondary hyperparathyroidism (SHPT) in patients and rats with chronic renal insufficiency (CRI). Calcimimetic compounds have been demonstrated to improve the decreased sensitivity of CaR to extracellular calcium concentration and to suppress both parathyroid hormone (PTH) oversecretion and parathyroid cell proliferation. However, the effect of calcimimetics on the reduced CaR expression level in parathyroid cells in CRI remains unclarified. The aim of this investigation was to examine the effect of the calcimimetic compound NSP R-568 (R-568) on the CaR expression in the parathyroid cells of rats with experimental CRI. Subtotally nephrectomized rats were fed a high-phosphorus diet for 8 (n = 12; Nx-8 group) or 9 wk (n = 11; Nx-9 group) to induce severe SHPT. Another group of uremic rats were fed a high-phosphorus diet for 8 wk and then orally administered R-568 (100 micromol/kg body wt) once a day for 7 d (n = 11; Nx+R-568 group). Sham-operated rats that were fed a standard diet for 9 wk were used as controls (n = 8). R-568 treatment induced a significant reduction in plasma PTH level with significant decrease in serum calcium and without change in serum phosphorus concentration. Serum 1,25(OH)2D3 level was not affected by R-568 administration. CaR mRNA and protein levels in the Nx-8 and Nx-9 groups significantly decreased compared with those in the controls; however, no significant difference in these parameters was observed between the Nx-8 and Nx-9 groups. In the Nx+R-568 group, CaR mRNA and protein levels significantly increased compared with those in either the Nx-8 or Nx-9 group. R-568 was effective in reducing the number of proliferating cell nuclear antigen-positive cells along with parathyroid gland growth suppression in the Nx+R-568 group compared with that in the Nx-9 group. The results suggest that the calcimimetic compound R-568 upregulates decreased CaR expression, and the upregulation possibly has an enhancement effect on PTH secretion and parathyroid cell hyperplasia through the improved sensitivity of CaR to [Ca2+]o.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466262     DOI: 10.1097/01.ASN.0000141016.20133.33

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  23 in total

Review 1.  Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations.

Authors:  Ogo I Egbuna; Edward M Brown
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098

Review 2.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

3.  Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism.

Authors:  Masahiro Yamamoto; Hiroaki Ogata; Masahide Mizobuchi; Noriyo Yoshida; Chiaki Kumata-Maeta; Fumihiko Koiwa; Kanji Shishido; Eriko Kinugasa
Journal:  Clin Exp Nephrol       Date:  2011-10-20       Impact factor: 2.801

4.  Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.

Authors:  Takehisa Kawata; Yasuo Imanishi; Keisuke Kobayashi; Naoyoshi Onoda; Senji Okuno; Yoshiaki Takemoto; Takeshi Komo; Hideki Tahara; Michihito Wada; Nobuo Nagano; Eiji Ishimura; Takami Miki; Tetsuro Ishikawa; Masaaki Inaba; Yoshiki Nishizawa
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 5.  New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

Authors:  Jorge B Cannata-Andía; Minerva Rodriguez-García; Pablo Román-García; Diego Tuñón-le Poultel; Francisco López-Hernández; Diego Rodríguez-Puyol
Journal:  Pediatr Nephrol       Date:  2010-02-12       Impact factor: 3.714

6.  Calcium-sensing receptor biosynthesis includes a cotranslational conformational checkpoint and endoplasmic reticulum retention.

Authors:  Alice Cavanaugh; Jennifer McKenna; Ann Stepanchick; Gerda E Breitwieser
Journal:  J Biol Chem       Date:  2010-04-26       Impact factor: 5.157

7.  Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study.

Authors:  Emanuel Zitt; Christine Jäger; Alexander R Rosenkranz; Manfred Eigner; Katharina Kodras; Josef Kovarik; Helmut Graf; Frank Pétavy; Sabine Horn; Bruno Watschinger
Journal:  Wien Klin Wochenschr       Date:  2011-01-21       Impact factor: 1.704

Review 8.  Minireview: the intimate link between calcium sensing receptor trafficking and signaling: implications for disorders of calcium homeostasis.

Authors:  Gerda E Breitwieser
Journal:  Mol Endocrinol       Date:  2012-06-28

9.  Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism.

Authors:  Yuki Tsuruta; Kazuhiro Okano; Kan Kikuchi; Yukio Tsuruta; Takashi Akiba; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-07-26       Impact factor: 2.801

Review 10.  Novel regulatory aspects of the extracellular Ca2+-sensing receptor, CaR.

Authors:  Daniela Riccardi; Brenda A Finney; William J Wilkinson; Paul J Kemp
Journal:  Pflugers Arch       Date:  2009-05-30       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.